By Rob Curran
Solid Biosciences received the Food and Drug Administration's fast-track designation for a gene therapy intended to treat a condition known as Friedreich's ataxia.
Solid Biosciences will move the SGT-212 therapy into a Phase 1b early-stage clinical trial for patients with Friedreich's ataxia, a genetic condition that causes difficulties with balance, among other nervous-system symptoms. Dosing with the therapy, which comprises delivery of a frataxin gene in two different ways, will begin in the second half of the year, the company said.
Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would have otherwise been possible. The FDA uses it for the treatment of serious conditions or unmet medical needs.
Shares of Solid Biosciences slipped 1.8% premarket.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 21, 2025 09:07 ET (14:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。